Phase II Exploratory Study of Immune Responses in Patients With Metastatic Melanoma Treated With Mouse Monoclonal Anti-OX40

Trial Profile

Phase II Exploratory Study of Immune Responses in Patients With Metastatic Melanoma Treated With Mouse Monoclonal Anti-OX40

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2013

At a glance

  • Drugs MEDI 6469 (Primary)
  • Indications Malignant melanoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Sep 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 17 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top